Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S have entered into a long-term agreement for the development and commercialization of as many as five innovative psychiatric and neuroscience products worldwide. The agreement covers early and late stage compounds in development. The two late stage compounds are from Otsuka: aripiprazole depot formulation and OPC-34712. Otsuka has rights to enter into co-development, and co-promotion following approval, of as many as three compounds after Phase ...